Found 15 matching trials
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C PHASE3 This study is to evaluate the overall efficacy, and safety profile of the t...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study PHASE3 Follow-up for viral activity, changes in liver function and safety in patie...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients NA The purpose of this study is to compare several Debio 025 (alisporivir)/peg...
Show More Location
Cliniques Universitaires Saint-Luc
Learn More & Join Trial
Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects PHASE1 The primary objective of the study was to compare the single dose pharmacok...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option PHASE2 The primary purpose of this study is to evaluate the pharmacodynamic (i.e. ...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment PHASE2 The study is to investigate whether participants with hepatitis C virus (HC...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1 PHASE3 This study will assess the safety and efficacy of alisporivir (ALV) and boc...
Show More Location
Novartis Investigational Site
Learn More & Join Trial
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients NA This study will explore the relationship of different DEB025 doses in combi...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants PHASE3 This study will assess the safety and efficacy of alisporivir (ALV; DEB025)...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19) PHASE2 COVID-19 is a viral respiratory and systemic disease that has been rapidly ...
Show More Location
Assistance Publique Hôpitaux de Paris - CHU Henri Mondor
Learn More & Join Trial